Physician profile
Paul R Epp
NPI 1770592461
$1,019.01
in general payments reported to CMS, 2019-2025
16 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $76.40 · 2021: $122 · 2022: $12.72 · 2024: $28.34 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $181.49 | 2019-2021 | |
| Alkermes, INC. | $134.96 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $122.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $116.98 | 2019-2022 | |
| Allergan, INC. | $95.97 | 2019-2020 | |
| Abbvie INC. | $85.17 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.45 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.41 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $32.33 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.48 | 2020-2025 | Uzedy |
| Shire North American Group INC | $24.57 | 2019 | |
| Abbott Laboratories | $23.06 | 2025 | Eterna |
| Lundbeck LLC | $21.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.65 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $14.95 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Epp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.